Research ArticleTheranostics
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn and Jeremie Calais
Journal of Nuclear Medicine August 2020, 61 (8) 1171-1177; DOI: https://doi.org/10.2967/jnumed.119.236786
Catherine Meyer
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Magnus Dahlbom
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Thomas Lindner
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Sebastien Vauclin
4DOSIsoft SA, Cachan, France
Christine Mona
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Roger Slavik
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
Johannes Czernin
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
6Institute of Urologic Oncology, UCLA, Los Angeles, California
7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
Uwe Haberkorn
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
8Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
Jeremie Calais
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
6Institute of Urologic Oncology, UCLA, Los Angeles, California

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 8
August 1, 2020
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1171-1177; DOI: 10.2967/jnumed.119.236786
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1171-1177; DOI: 10.2967/jnumed.119.236786
Jump to section
Related Articles
Cited By...
- Evaluation of Fibroblast Activation Protein Expression Using 68Ga-FAPI46 PET in Hypertension-Induced Tissue Changes
- Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients
- Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors
- 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG
- Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis
- Incidental Focal 68Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion
- Could FAP-Targeted Molecular Imaging Replace 18F-FDG for Standard-of-Care Oncologic PET?
- Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
- PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake
- Dual-Tracer PET/CT Protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept
- Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer
- Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
- An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
- FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
- The Latest Developments in Imaging of Fibroblast Activation Protein
- Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
- FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients